Plutux
$4.41
-1.05%
2026-09-04 12:19:19 EDT-$0.05
Healthcare
Medical - Care Facilities
NYSE
Active Trading

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of ...

Price Action

$4.41
-1.05%-$0.05
High
Low
52W High-36.8%
Rel. vol
Interval
Range81m
VolumeSMA5SMA10
Concord Medical Services Holdings Limited (NYSE: CCM) is a China-focused healthcare services company that operates radiotherapy and diagnostic imaging facilities. The company’s core operations are centered on delivering cancer treatment and diagnostic services through an established network of centers and specialty cancer hospital offerings. In business terms, Concord Medical combines ...Concord Medical Services Holdings Limited (NYSE: CCM) is a China-focused healthcare services company that operates radiotherapy and diagnostic imaging facilities. The company’s core operations are centered on delivering cancer treatment and diagnostic services through an established network of centers and specialty cancer hospital offerings. In business terms, Concord Medical combines clinical service delivery with supporting operational services that help hospitals and physicians coordinate care, including developing treatment protocols, supporting joint diagnosis, and providing clinical research-related support. From a product and service perspective, the company’s offerings span multiple modalities used in oncology pathways. In radiotherapy, it provides treatment capabilities that include linear accelerator and external beam radiotherapy services, proton therapy systems, and radiosurgery platforms such as gamma knife. In diagnostics, it offers imaging services using modalities such as PET-CT and MRI. Beyond direct clinical delivery, the company supports hospitals via radiotherapy and diagnostic equipment leasing, equipment management services, and premium cancer/proton treatment services. It also provides teleconsultation and medical information technology services, which are intended to extend specialist expertise and coordinate care across sites. The company reports business segments commonly described as “Network” and “Hospital.” The “Network” model reflects operating radiotherapy and diagnostic imaging centers, while “Hospital” reflects involvement in specialty cancer hospital operations, typically encompassing radiation, imaging, testing laboratory capabilities, inpatient/nursing services, and related oncology workflows. This service mix indicates a relatively integrated approach across diagnosis, treatment, and ongoing clinical operations. Regarding cost structure and “BOM”-like considerations (materials and capital inputs), radiotherapy and imaging are capital-intensive, relying on sophisticated medical equipment (e.g., radiation delivery systems and imaging scanners) and specialized clinical staffing. While the provided dataset does not list specific bill-of-materials items, the operational economics of such centers typically involve capital depreciation/amortization, maintenance, consumables for imaging and treatment delivery, and personnel costs for radiation oncologists, medical physicists, imaging technologists, nurses, and support staff. Additionally, leasing and management services suggest the company can monetize access to equipment through contractual arrangements rather than solely owning all assets. Financially, the supplied snapshot data indicates profitability pressures, with negative operating/EBIT/EBITDA/net profit margins in the latest trailing-twelve-month (TTM) view (e.g., gross margin around 6.9% and operating profit margin around -40.9%). Liquidity indicators provided also suggest constrained current liquidity (current ratio below 1 in the dataset) and relatively low solvency ratio values. These metrics imply that the business may be in a period where costs, utilization, pricing, reimbursement dynamics, or investment cycles influence earnings. In terms of key people, Dr. Jianyu Yang serves as Chairman and Chief Executive Officer (and president) and has been in that leadership role since 2007, positioning him as the central executive figure guiding strategy and operations. With headquarters in Beijing, China, and an employee count of about 610, Concord Medical fits the scale of a mid-sized healthcare services operator managing specialized clinical sites and associated support functions. Overall, Concord Medical’s “wish” or strategic direction is consistent with being a leading provider of oncology-related radiotherapy and imaging services in China—expanding and operating clinical capacity, enhancing technology platforms, and supporting hospitals and physician networks through integrated clinical support, information technology, and equipment-related services.
Founded
1997
Employees
610
CEO
Jianyu Yang
Full Name
Concord Medical Services Holdings Limited
Sector
Healthcare
Industry
Medical - Care Facilities
ROE
5.73%
Market Cap
$0.02B
Current Ratio
0.48
WACC
2.13%
ROIC
-6.95%

Contact Information

86 10 5903 6688
East Zone, Hanwei Plaza, Beijing, NY 100020

Related stocksMedical - Care Facilities

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026